PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Dihydrocodeine tartrate - Pain

PAD Profile : Dihydrocodeine tartrate - Pain

Keywords :
Dihydrocodeine, weak opioid, opioid analgesics, analgesia

Traffic Light Status

Status 1 of 2.

Status :
Green
Formulations :
  • Oral solution
  • Tablets
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
CD
Comments :
No comments returned.
Documents :

Status 2 of 2.

Status :
Green (see narrative)
Important
Formulations :
  • Modified release tablets
Important Information :
Consider use if standard release tablets are not tolerated or compliance is an issue.
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
CD
Comments :
No comments returned.
Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

No indications returned.

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
06 June 2018
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

Persistent Non-Malignant Pain Guidelines
A stepped approach to pain management is recommended. Paracetamol is considered a 1st line option for the treatment of persistent non-malignant pain. A trial of codeine should be initiated where a weak opioid is indicated. Please see narrative below regarding specific  products. Refer to specific pages on PAD for products containing codeine phosphate (including combination products) and refer to persistent non-maligant pain guidelines attached: 

  • Dihydrocodeine (standard release) 30mg tablets - GREEN
  • Dihydrocodeine oral solution - GREEN (treatment option if oral solution is indicated)
  • Dihydrocodeine sustained release tablets - GREEN  (use if standard release tablets are not tolerated or compliance is an issue. Initiate at a low dose).

Consider a patient agreement is completed by the patient (see below) prior to a trial of Dihydrocodeine

Associated BNF Codes

04. Central Nervous System
04.07.02. Opioid analgesics
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More